Strategic Initiative

Slingshot members are tracking this corporate initiative:

BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BLRX

100%

Additional Information

Additional Relevant Details
  • BioLineRx has signed an exclusive worldwide agreement with Hadasit, theTechnology Transfer Company of Hadassah Medical Organization, for the in-licensing of a drug candidate for the treatment of liver fibrosis, and in particular, non-alcoholic steatohepatitis (NASH). This drug candidate, to be called BL-1210, is the first project to be in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.The newly in-licensed pre-clinical project, developed by Prof. Rifaat Safadi, Head of the Liver Unit, Department of Medicine at Hadassah Medical Center, Jerusalem, Israel, offers a novel mechanism for controlling liver fibrosis through modulation of the immune system. BioLineRx will address the novel drug target that will modulate the immune system to ultimately reduce the liver fibrogenesis and therefore reduce liver scarring. Limiting the fibrosis process this way will potentially control the disease progression.
http://ir.biolinerx....
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Aug 01, 2016
Projected Implementation:
Q3, 2016
Relevance Tracked Until:
Q4, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Liver Fibrosis, Bl-1210, Liver Scarring